<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733430</url>
  </required_header>
  <id_info>
    <org_study_id>LALUCA Project Plan Version 5</org_study_id>
    <nct_id>NCT04733430</nct_id>
  </id_info>
  <brief_title>LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice</brief_title>
  <acronym>LALUCA</acronym>
  <official_title>Landsteiner Lung Cancer Research Platform (LALUCA) A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karl Landsteiner Institute for Lung Research and Pneumological Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karl Landsteiner Institute for Lung Research and Pneumological Oncology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world&#xD;
      setting. The aim of the project is to establish a clinical platform to collect representative&#xD;
      data on molecular testing, sequence of systemic tumor therapy and other therapies, and&#xD;
      disease progression of patients with lung cancer. A special focus will be on molecular&#xD;
      biomarker testing and reflex NGS testing. Another aim of the registry is the collection of&#xD;
      quality indicators in lung cancer care. The results of the register will be used to describe&#xD;
      the current state of care and to develop it further for the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The identification of driver-mutations, whose gene product can be specifically inhibited by&#xD;
      targeted therapies, has markedly changed the diagnostic and therapeutic landscape for this&#xD;
      tumor entity, leading to improved outcomes for patients with metastatic NSCLC.&#xD;
&#xD;
      The use of next generation sequencing (NGS) allows for detection of a multitude of different&#xD;
      druggable mutations. In absence of a curative treatment approach and a druggable mutation the&#xD;
      prognosis of lung cancer remains poor.&#xD;
&#xD;
      Thorough knowledge of the treatment reality, e.g. characteristics, diagnostic, treatment and&#xD;
      outcome of unselected patients in real-Iife practice, is crucial to evaluate and improve the&#xD;
      quality of care for patients with lung cancer.&#xD;
&#xD;
      The purpose of this project is to set up a clinical platform to document representative data&#xD;
      on molecular testing, sequence of systemic treatment and other treatment modalities, and&#xD;
      course of disease in patients with lung cancer. A particular focus is on molecular biomarker&#xD;
      testing and NGS of patients before the start of first-line treatment. The data shall be used&#xD;
      to assess the current state of care and to develop recommendations concerning topics that can&#xD;
      be improved.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">April 2030</completion_date>
  <primary_completion_date type="Anticipated">April 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>NGS Testing</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>To assess molecular biomarker testing and indicators of the quality of care in patients with lung cancer</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All unselected patients diagnosed with lung cancer at the research sites. The study is&#xD;
        intended to commence at two sites in Vienna, with subsequent invitation of participation of&#xD;
        other sites.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Histologically confirmed lung cancer&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Able to understand and willing to sign written Informed Consent and to complete&#xD;
             patient-reported-outcome assessment instruments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>125 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georg-Christian Funk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Medical Department with Pneumology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georg-Christian Funk, MD</last_name>
    <phone>+43 1 4000-2203</phone>
    <email>georg-christian.funk@gesundheitsverbund.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnes Attoh, BSc</last_name>
    <phone>+43 1 4000-72203</phone>
    <email>agnes.attoh@extern.gesundheitsverbund.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg-Christian Funk, MD</last_name>
      <phone>+4314000-2203</phone>
      <email>georg-christian.funk@gesundheitsverbund.at</email>
    </contact>
    <contact_backup>
      <last_name>Agnes Attoh</last_name>
      <phone>+4314000-72203</phone>
      <email>agnes.attoh@extern.gesundheitsverbund.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NGS Testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

